Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
Peking University Cancer Hospital · Peking University · +36 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
46
total citations
- FWCI
- 52.55
- Percentile
- 100%
- References
- 29
Citations per year
Authors
45- XZXiaotian ZhangCorresponding
Peking University Cancer Hospital, Peking University
- LHLiang Han
Tianjin Medical University Cancer Institute and Hospital
- ZLZiyu Li
Peking University, Peking University Cancer Hospital
- YXYingwei Xue
Harbin Medical University, Third Affiliated Hospital of Harbin Medical University
- YWYanong Wang
Fudan University Shanghai Cancer Center, Peking University, Peking University Cancer Hospital
Topics & keywords
Topics
Keywords
- Oxaliplatin
- Capecitabine
- Medicine
- Adjuvant
- Gastric adenocarcinoma
- Perioperative
- Gastrectomy
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.